Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Sutariya BK, Patel MS, Bahekar RH, Jain MR.

Curr Mol Pharmacol. 2019;12(2):139-146. doi: 10.2174/1874467212666190212112402.

PMID:
30747091
2.

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Sutariya BK, Patel MS, Patel HM, Pandey DK, Bahekar RH, Jain MR.

World J Diabetes. 2018 Jun 15;9(6):80-91. doi: 10.4239/wjd.v9.i6.80.

3.

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.

Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR.

J Med Chem. 2018 Aug 23;61(16):6964-6982. doi: 10.1021/acs.jmedchem.7b01686. Epub 2018 May 9. Review.

PMID:
29712435
4.

Erratum. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609-2623.

Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N.

Diabetes. 2017 Dec;66(12):3142-3143. doi: 10.2337/db17-er12b. Epub 2017 Oct 5. No abstract available.

5.

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.

Jain MR, Joharapurkar AA, Kshirsagar SG, Patel VJ, Bahekar RH, Patel HV, Jadav PA, Patel PR, Desai RC.

Br J Pharmacol. 2017 Jul;174(14):2346-2357. doi: 10.1111/bph.13842. Epub 2017 Jun 13.

6.

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.

Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC.

Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3.

PMID:
28158894
7.

Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.

Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR, Desai RC.

Xenobiotica. 2018 Jan;48(1):37-44. doi: 10.1080/00498254.2016.1278287. Epub 2017 Jan 19.

PMID:
28042744
8.

Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.

Patel V, Joharapurkar AA, Kshirsagar SG, Patel KN, Bahekar R, Shah G, Jain MR.

Can J Physiol Pharmacol. 2016 Feb;94(2):161-167. doi: 10.1139/cjpp-2014-0457. Epub 2015 Jul 29.

PMID:
26629909
9.

Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.

Jain MR, Joharapurkar AA, Pandya V, Patel V, Joshi J, Kshirsagar S, Patel K, Patel PR, Desai RC.

Drug Res (Stuttg). 2016 Feb;66(2):107-12. doi: 10.1055/s-0035-1554630. Epub 2015 Sep 14.

PMID:
26367279
10.

Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia.

Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N.

Diabetes. 2015 Jul;64(7):2609-23. doi: 10.2337/db14-1611. Epub 2015 Jan 29. Erratum in: Diabetes. 2017 Dec;66(12 ):3142-3143.

11.

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors.

Patel JZ, Nevalainen TJ, Savinainen JR, Adams Y, Laitinen T, Runyon RS, Vaara M, Ahenkorah S, Kaczor AA, Navia-Paldanius D, Gynther M, Aaltonen N, Joharapurkar AA, Jain MR, Haka AS, Maxfield FR, Laitinen JT, Parkkari T.

ChemMedChem. 2015 Feb;10(2):253-65. doi: 10.1002/cmdc.201402453. Epub 2014 Dec 11.

12.

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.

Can J Physiol Pharmacol. 2014 Dec;92(12):975-83. doi: 10.1139/cjpp-2014-0310. Epub 2014 Sep 29.

PMID:
25361428
13.

Therapeutic potential of coagonists of glucagon and GLP-1.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Patel KN, Shah GB, Jain MR.

Cardiovasc Hematol Agents Med Chem. 2014;12(2):126-33. Review.

PMID:
25330114
14.

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.

Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC.

J Diabetes. 2015 Sep;7(5):708-17. doi: 10.1111/1753-0407.12233. Epub 2014 Dec 17.

PMID:
25327540
15.

Effect of GLP-1 based therapies on diabetic dyslipidemia.

Patel VJ, Joharapurkar AA, Shah GB, Jain MR.

Curr Diabetes Rev. 2014;10(4):238-50. Review.

PMID:
24998439
16.

Orally active osteoanabolic agent GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling, and improves metabolic health in a rodent model of diabetes.

Singh AK, Joharapurkar AA, Khan MP, Mishra JS, Singh N, Yadav M, Hossain Z, Khan K, Kumar S, Dhanesha NA, Mishra DP, Maurya R, Sharma S, Jain MR, Trivedi AK, Godbole MM, Gayen JR, Chattopadhyay N, Sanyal S.

Diabetes. 2014 Oct;63(10):3530-44. doi: 10.2337/db13-1619. Epub 2014 May 21.

17.

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity.

Joharapurkar AA, Dhanesha NA, Jain MR.

Diabetes Metab Syndr Obes. 2014 Feb 28;7:73-84. doi: 10.2147/DMSO.S56924. eCollection 2014. Review.

18.

Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.

Joharapurkar AA, Dhote VV, Jain MR.

J Med Chem. 2012 Jun 28;55(12):5649-75. doi: 10.1021/jm2004706. Epub 2012 May 1. Review. No abstract available.

PMID:
22512468
19.

Antinociceptive activity of alcoholic extract of Hemidesmus indicus R.Br. in mice.

Verma PR, Joharapurkar AA, Chatpalliwar VA, Asnani AJ.

J Ethnopharmacol. 2005 Nov 14;102(2):298-301. Epub 2005 Aug 2.

PMID:
16081231

Supplemental Content

Loading ...
Support Center